1.
ACS Med Chem Lett
; 13(4): 658-664, 2022 Apr 14.
Artículo
en Inglés
| MEDLINE
| ID: mdl-35450354
RESUMEN
Inappropriate activation of TLR7 and TLR8 is linked to several autoimmune diseases, such as lupus erythematosus. Here we report on the efficient structure-based optimization of the inhibition of TLR8, starting from a co-crystal structure of a small screening hit. Further optimization of the physicochemical properties for cellular potency and expansion of the structure-activity relationship for dual potency finally resulted in a highly potent TLR7/8 antagonist with demonstrated in vivo efficacy after oral dosing.